The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737*

Background: Mcl-1 inhibits apoptosis and promotes survival of cancer cells. Results: The Hsp70 co-chaperone, BAG3, prevents Mcl-1 degradation by the proteasome. Conclusion: BAG3 sustains Mcl-1 expression in cancer cells, promoting its antiapoptotic activity. Significance: Mcl-1 expression is a major determinant of resistance in human cancer, so BAG3 is a potential target for anticancer drug discovery. Members of the Bcl-2 family of proteins are important inhibitors of apoptosis in human cancer and are targets for novel anticancer agents such as the Bcl-2 antagonists, ABT-263 (Navitoclax), and its analog ABT-737. Unlike Bcl-2, Mcl-1 is not antagonized by ABT-263 or ABT-737 and is considered to be a major factor in resistance. Also, Mcl-1 exhibits differential regulation when compared with other Bcl-2 family members and is a target for anticancer drug discovery. Here, we demonstrate that BAG3, an Hsp70 co-chaperone, protects Mcl-1 from proteasomal degradation, thereby promoting its antiapoptotic activity. Using neuroblastoma cell lines, with a defined Bcl-2 family dependence, we found that BAG3 expression correlated with Mcl-1 dependence and ABT-737 resistance. RNA silencing of BAG3 led to a marked reduction in Mcl-1 protein levels and overcame ABT-737 resistance in Mcl-1-dependent cells. In ABT-737-resistant cells, Mcl-1 co-immunoprecipitated with BAG3, and loss of Mcl-1 after BAG3 silencing was prevented by proteasome inhibition. BAG3 and Mcl-1 were co-expressed in a panel of diverse cancer cell lines resistant to ABT-737. Silencing BAG3 reduced Mcl-1 protein levels and overcame ABT-737 resistance in several of the cell lines, including triple-negative breast cancer (MDA-MB231) and androgen receptor-negative prostate cancer (PC3) cells. These studies identify BAG3-mediated Mcl-1 stabilization as a potential target for cancer drug discovery.

[1]  Marc L. Mendillo,et al.  HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers , 2012, Cell.

[2]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[3]  P. Fisher,et al.  Targeting Mcl-1 for the therapy of cancer , 2011, Expert opinion on investigational drugs.

[4]  U. Wolfrum,et al.  BAG3 mediates chaperone‐based aggresome‐targeting and selective autophagy of misfolded proteins , 2011, EMBO reports.

[5]  K. Khalili,et al.  BAG3 Expression in Glioblastoma Cells Promotes Accumulation of Ubiquitinated Clients in an Hsp70-dependent Manner* , 2011, The Journal of Biological Chemistry.

[6]  M. Butterworth,et al.  Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells , 2010, Haematologica.

[7]  Jian-yong Li,et al.  [Bag3 gene expression in chronic lymphocytic leukemia and its association with patients' prognosis]. , 2010, Zhongguo shi yan xue ye xue za zhi.

[8]  Daniel P. Stewart,et al.  Ubiquitin-Independent Degradation of Antiapoptotic MCL-1 , 2010, Molecular and Cellular Biology.

[9]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[10]  F. Bazan,et al.  Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival , 2010, Nature.

[11]  M. Hogarty,et al.  BH3 Response Profiles From Neuroblastoma Mitochondria Predict Activity of Small Molecule Bcl-2 Family Antagonists , 2009, Cell Death and Differentiation.

[12]  M. Hogarty,et al.  Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists , 2009, Cancer biology & therapy.

[13]  L. Marnett,et al.  HSF1-mediated BAG3 Expression Attenuates Apoptosis in 4-Hydroxynonenal-treated Colon Cancer Cells via Stabilization of Anti-apoptotic Bcl-2 Proteins* , 2009, Journal of Biological Chemistry.

[14]  C. Akgul.  Mcl-1 is a potential therapeutic target in multiple types of cancer , 2009, Cellular and Molecular Life Sciences.

[15]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[16]  Gudrun Schleiermacher,et al.  Overall genomic pattern is a predictor of outcome in neuroblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Hartl,et al.  Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3 , 2009, The EMBO journal.

[18]  F. Muntoni,et al.  Mutation in BAG3 causes severe dominant childhood muscular dystrophy , 2008, Annals of neurology.

[19]  G. Chinnadurai,et al.  BH3-only proteins in apoptosis and beyond: an overview , 2008, Oncogene.

[20]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[21]  M. Hung,et al.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. , 2008, Cancer research.

[22]  John Calvin Reed,et al.  BAG3 regulates motility and adhesion of epithelial cancer cells. , 2007, Cancer research.

[23]  S. Lindquist,et al.  Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis , 2007, Cell.

[24]  A. Gentilella,et al.  Apoptosis inhibition in cancer cells: a novel molecular pathway that involves BAG3 protein. , 2007, The international journal of biochemistry & cell biology.

[25]  M. Todaro,et al.  The antiapoptotic protein BAG3 is expressed in thyroid carcinomas and modulates apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. , 2007, The Journal of clinical endocrinology and metabolism.

[26]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[27]  C. Tse,et al.  Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. , 2007, Cancer research.

[28]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[29]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[30]  John Calvin Reed,et al.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. , 2006, Cancer cell.

[31]  John Calvin Reed,et al.  BAG3 deficiency results in fulminant myopathy and early lethality. , 2006, The American journal of pathology.

[32]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[33]  D. Green,et al.  Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. , 2006, Molecular cell.

[34]  M. Hogarty,et al.  Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. , 2005, Cancer letters.

[35]  Adam A. Margolin,et al.  High‐resolution detection and mapping of genomic DNA alterations in neuroblastoma , 2005, Genes, chromosomes & cancer.

[36]  Xiaodong Wang,et al.  Mule/ARF-BP1, a BH3-Only E3 Ubiquitin Ligase, Catalyzes the Polyubiquitination of Mcl-1 and Regulates Apoptosis , 2005, Cell.

[37]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[38]  S. Derdak,et al.  Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. , 2005, Blood.

[39]  Dan Xu,et al.  Specific Cleavage of Mcl-1 by Caspase-3 in Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis in Jurkat Leukemia T Cells* , 2005, Journal of Biological Chemistry.

[40]  T. McDonnell,et al.  MCL-1 expression in B-cell non-Hodgkin's lymphomas. , 2004, Human pathology.

[41]  R. Craig,et al.  MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol , 2004, Oncogene.

[42]  J. Clohessy,et al.  Characterisation of Mcl‐1 cleavage during apoptosis of haematopoietic cells , 2004, British journal of haematology.

[43]  Ajay N. Jain,et al.  Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. , 2003, Cancer research.

[44]  E. Kohn,et al.  CAIR-1/BAG-3 Abrogates Heat Shock Protein-70 Chaperone Complex-mediated Protein Degradation , 2003, Journal of Biological Chemistry.

[45]  Barbara Hero,et al.  Neuroblastoma: biology and molecular and chromosomal pathology. , 2003, The Lancet. Oncology.

[46]  Wenhua Gao,et al.  Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. , 2003, Genes & development.

[47]  E. Kohn,et al.  What's in the 'BAG'?--A functional domain analysis of the BAG-family proteins. , 2002, Cancer letters.

[48]  H. Ichijo,et al.  Phosphorylation and Inactivation of Myeloid Cell Leukemia 1 by JNK in Response to Oxidative Stress* , 2002, The Journal of Biological Chemistry.

[49]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[50]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[51]  R. Craig.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis , 2002, Leukemia.

[52]  D. Green,et al.  A Matter of Life and Death , 2008, Science.

[53]  H. Friess,et al.  The anti‐apoptotic protein BAG‐3 is overexpressed in pancreatic cancer and induced by heat stress in pancreatic cancer cell lines , 2001, FEBS letters.

[54]  S. Edwards,et al.  In vivo localisation and stability of human Mcl‐1 using green fluorescent protein (GFP) fusion proteins , 2000, FEBS letters.

[55]  S. Rabindran,et al.  A novel association between the human heat shock transcription factor 1 (HSF1) and prostate adenocarcinoma. , 2000, The American journal of pathology.

[56]  J. Höhfeld,et al.  The Ubiquitin-related BAG-1 Provides a Link between the Molecular Chaperones Hsc70/Hsp70 and the Proteasome* , 2000, The Journal of Biological Chemistry.

[57]  Y. Tsujimoto,et al.  Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death , 1999, Oncogene.

[58]  John Calvin Reed,et al.  An Evolutionarily Conserved Family of Hsp70/Hsc70 Molecular Chaperone Regulators* , 1999, The Journal of Biological Chemistry.

[59]  John Calvin Reed,et al.  BAG‐1 modulates the chaperone activity of Hsp70/Hsc70 , 1997, The EMBO journal.

[60]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[61]  R. Craig,et al.  The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2 , 1995, The Journal of cell biology.

[62]  John Calvin Reed,et al.  Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity , 1995, Cell.

[63]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[64]  P. Nowell,et al.  Oncogenic potential of bcl-2 demonstrated by gene transfer , 1988, Nature.

[65]  R. Gascoyne,et al.  Short Communication Immunohistochemical Analysis of Mci-1 Protein in Human Tissues Differential Regulation of Mcl- 1 and Bcl-2 Protein Production Suggests a Unique Role for Mcl- 1 in Control of Programmed Cell Death In Vivo , 2007 .

[66]  M. Peck-Radosavljevic,et al.  Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. , 2006, Journal of hepatology.

[67]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[68]  M. Hogarty,et al.  Molecular and Cellular Pathobiology Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma , 2022 .